Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE -301.8%. (1995–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2M | $43M | $96M | $24M | $109M | $326M | $296M | $341M | $200M | $64M | $31M |
| Enterprise Value | $11M | $52M | $100M | $-21339056 | $75M | $272M | $245M | $258M | $158M | $39M | $27M |
| P/E Ratio → | -0.06 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.08 | 1.52 | 2.82 | 0.57 | 3.61 | 21.52 | 71.77 | — | — | — | 652.83 |
| P/B Ratio | 1.25 | 23.45 | 3.96 | 0.36 | 1.01 | 3.15 | 3.17 | 3.11 | 5.19 | 3.09 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.83 | 2.95 | -0.50 | 2.47 | 17.96 | 59.32 | — | — | — | 575.99 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | 4.07 | 3.81 |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 39.1% | 39.1% | 59.2% | 63.3% | 58.4% | 37.2% | 4.7% | — | — | — | 86.9% |
| Operating Margin | -138.8% | -138.8% | -74.0% | -61.5% | -137.6% | -348.6% | -968.1% | — | — | — | 14990.8% |
| Net Profit Margin | -137.6% | -137.6% | -79.5% | -95.1% | -121.5% | -318.9% | -1098.1% | — | — | — | -15104.0% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -301.8% | -301.8% | -59.1% | -46.9% | -34.7% | -49.0% | -44.7% | -37.1% | -36.3% | -128.7% | — |
| ROA | -60.9% | -60.9% | -31.4% | -35.0% | -27.6% | -41.9% | -42.0% | -34.7% | -29.6% | -56.4% | -84.1% |
| ROIC | -153.0% | -153.0% | -76.0% | -41.9% | -50.5% | -86.1% | -86.9% | -170.6% | — | — | — |
| ROCE | -104.6% | -104.6% | -36.4% | -25.9% | -33.9% | -49.2% | -39.2% | -35.4% | -32.4% | 60.4% | 94.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 11.96 | 11.96 | 0.88 | 0.02 | 0.04 | 0.03 | 0.02 | 0.01 | 0.04 | 0.07 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | 0.16 | 0.20 |
| Net Debt / Equity | — | 4.69 | 0.17 | -0.68 | -0.32 | -0.52 | -0.55 | -0.76 | -1.09 | -1.23 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | -2.70 | -0.51 |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -42.71 | -42.71 | — | -427.27 | — | — | — | -3345.93 | -718.16 | -278.62 | -86.40 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.09 | 1.09 | 3.55 | 4.32 | 4.70 | 9.28 | 7.74 | 23.89 | 8.65 | 20.86 | 5.29 |
| Quick Ratio | 0.94 | 0.94 | 2.60 | 3.96 | 4.56 | 9.11 | 7.17 | 23.82 | 8.65 | 20.86 | 5.29 |
| Cash Ratio | 0.44 | 0.44 | 1.84 | 3.02 | 3.68 | 8.32 | 6.83 | 21.97 | 8.59 | 20.59 | 4.87 |
| Asset Turnover | — | 0.53 | 0.45 | 0.45 | 0.22 | 0.12 | 0.04 | — | — | — | 0.01 |
| Inventory Turnover | 3.31 | 3.31 | 0.87 | 2.58 | 6.58 | 7.01 | 0.87 | 5.90 | — | — | — |
| Days Sales Outstanding | — | 196.27 | 109.22 | 109.85 | 118.61 | 111.98 | 114.24 | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 31.1% | 1.7% | 0.8% | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.3% | 13.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 31.1% | 1.7% | 1.1% | 13.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $15M | $13M | $14M | $14M | $11M | $10M | $8M | $6M | $6M | $3M |
Imminent liquidity and solvency
According to recent market data, CASI trades at a P/S multiple of 0.08, a figure that, while appearing deeply undervalued, likely reflects the market's skepticism regarding the firm's ability to achieve commercial scale and navigate the regulatory complexities inherent in its China-centric business model.
The extremely low P/S ratio suggests that investors are pricing the company as a distressed asset rather than a growth-stage biotech. This valuation multiple warrants caution, as it may not account for the potential for significant equity dilution required to sustain operations given the current cash burn.
Based on reported financial statements, the company's ROIC has deteriorated to -154.9% in 2025Q1, illustrating a persistent inability to generate returns on invested capital that exceed the cost of funding its extensive clinical and commercial infrastructure.
The consistent negative trend in ROIC indicates that every dollar of capital deployed is currently destroying shareholder value rather than compounding it. This decay suggests that the current in-licensing strategy is failing to produce the necessary margin expansion to offset the high fixed costs of the business.
As reported in recent filings, the cash conversion cycle has expanded to 209 days in 2025Q3, a significant inefficiency that highlights the company's struggle to manage inventory and collect receivables within the complex Chinese hospital procurement environment.
The lengthening CCC suggests that the company is increasingly reliant on external financing to bridge the gap between product delivery and cash collection. Investors should monitor whether this trend is a structural feature of the Chinese distribution system or a sign of weakening bargaining power with hospital customers.
Based on the 2025Q3 balance sheet, the current ratio has fallen to 0.30, indicating that the company's liquid assets are insufficient to cover its short-term liabilities, which poses a severe risk to the firm's ongoing operational viability in the near term.
This liquidity profile suggests that the company is in a precarious position, with little room for error in its commercial execution or regulatory milestones. The reliance on short-term assets to cover obligations may force management into unfavorable financing arrangements that could further dilute existing shareholders.
The P/B ratio of 1.25 is frequently misapplied to CASI, as it obscures the reality that the company's book value is heavily influenced by intangible assets and licensing rights that may hold little liquidation value in a distressed scenario.
Analysts should instead focus on the cash-to-burn ratio, as the book value provides a misleading sense of security for a company with negative equity and persistent operating losses. Relying on traditional valuation multiples ignores the specific geopolitical and regulatory risks that define the company's true risk profile.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CASI stock.
CASI Pharmaceuticals, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
CASI Pharmaceuticals, Inc.'s return on equity (ROE) is -301.8%. The historical average is -144.9%.
Based on historical data, CASI Pharmaceuticals, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
CASI Pharmaceuticals, Inc.'s current dividend yield is 31.10%.
CASI Pharmaceuticals, Inc. has 39.1% gross margin and -138.8% operating margin.